Several previous meta-analyses and NMAs have compared the efficacy and safety of ALK inhibitors in ALK-p ALK-inhibitor–naïve advanced NSCLC [65,74,75,76,77,78,79,80]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.